Background: Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study. Methods: Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons. Results: Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided P = 3 × 10-4). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including BRCA1/2, FH, PALB2, PMS2, and CDKN2A. A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (NF1, SUFU, TSC1, PTCH2), Wilms tumor (WT1, REST), non-Hodgkin lymphoma (PMS2), and soft tissue sarcomas (SDHB, DICER1, TP53, ERCC4, FGFR3) compared with other pediatric cancers. Conclusion: In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families. Published by Oxford University Press 2021. This work is written by US Government employees and is in the public domain in the US.
Background: Pediatric cancers are the leading cause of death by disease in children despite improved survival rates overall. The contribution of germline genetic susceptibility to pediatric cancer survivors has not been extensively characterized. We assessed the frequency of pathogenic or likely pathogenic (P/LP) variants in 5451 long-term pediatric cancer survivors from the Childhood Cancer Survivor Study. Methods: Exome sequencing was conducted on germline DNA from 5451 pediatric cancer survivors (cases who survived ≥5 years from diagnosis; n = 5105 European) and 597 European cancer-free adults (controls). Analyses focused on comparing the frequency of rare P/LP variants in 237 cancer-susceptibility genes and a subset of 60 autosomal dominant high-to-moderate penetrance genes, for both case-case and case-control comparisons. Results: Of European cases, 4.1% harbored a P/LP variant in high-to-moderate penetrance autosomal dominant genes compared with 1.3% in controls (2-sided P = 3 × 10-4). The highest frequency of P/LP variants was in genes typically associated with adult onset rather than pediatric cancers, including BRCA1/2, FH, PALB2, PMS2, and CDKN2A. A statistically significant excess of P/LP variants, after correction for multiple tests, was detected in patients with central nervous system cancers (NF1, SUFU, TSC1, PTCH2), Wilms tumor (WT1, REST), non-Hodgkin lymphoma (PMS2), and soft tissue sarcomas (SDHB, DICER1, TP53, ERCC4, FGFR3) compared with other pediatric cancers. Conclusion: In long-term pediatric cancer survivors, we identified P/LP variants in cancer-susceptibility genes not previously associated with pediatric cancer as well as confirmed known associations. Further characterization of variants in these genes in pediatric cancer will be important to provide optimal genetic counseling for patients and their families. Published by Oxford University Press 2021. This work is written by US Government employees and is in the public domain in the US.
Authors: A Chompret; A Abel; D Stoppa-Lyonnet; L Brugiéres; S Pagés; J Feunteun; C Bonaïti-Pellié Journal: J Med Genet Date: 2001-01 Impact factor: 6.318
Authors: Carmen L Wilson; Zhaoming Wang; Qi Liu; Matthew J Ehrhardt; Roya Mostafavi; John Easton; Heather Mulder; Dale J Hedges; Shuoguo Wang; Michael Rusch; Michael Edmonson; Shawn Levy; Jennifer Q Lanctot; Kelsey Currie; Matthew Lear; Aman Patel; Yadav Sapkota; Russell J Brooke; Wonjong Moon; Ti-Cheng Chang; Wenan Chen; Chimene A Kesserwan; Gang Wu; Kim E Nichols; Melissa M Hudson; Jinghui Zhang; Leslie L Robison; Yutaka Yasui Journal: Pediatr Blood Cancer Date: 2019-11-17 Impact factor: 3.167
Authors: Rahul Krishnatry; Nataliya Zhukova; Ana S Guerreiro Stucklin; Jason D Pole; Matthew Mistry; Iris Fried; Vijay Ramaswamy; Ute Bartels; Annie Huang; Normand Laperriere; Peter Dirks; Paul C Nathan; Mark Greenberg; David Malkin; Cynthia Hawkins; Pratiti Bandopadhayay; Mark W Kieran; Peter E Manley; Eric Bouffet; Uri Tabori Journal: Cancer Date: 2016-03-10 Impact factor: 6.860
Authors: Lisa Mirabello; Bin Zhu; Roelof Koster; Eric Karlins; Michael Dean; Meredith Yeager; Matthew Gianferante; Logan G Spector; Lindsay M Morton; Danielle Karyadi; Leslie L Robison; Gregory T Armstrong; Smita Bhatia; Lei Song; Nathan Pankratz; Maisa Pinheiro; Julie M Gastier-Foster; Richard Gorlick; Silvia Regina Caminada de Toledo; Antonio S Petrilli; Ana Patino-Garcia; Fernando Lecanda; Miriam Gutierrez-Jimeno; Massimo Serra; Claudia Hattinger; Piero Picci; Katia Scotlandi; Adrienne M Flanagan; Roberto Tirabosco; Maria Fernanda Amary; Nilgün Kurucu; Inci Ergurhan Ilhan; Mandy L Ballinger; David M Thomas; Donald A Barkauskas; Gerardo Mejia-Baltodano; Patricia Valverde; Belynda D Hicks; Bin Zhu; Mingyi Wang; Amy A Hutchinson; Margaret Tucker; Joshua Sampson; Maria T Landi; Neal D Freedman; Susan Gapstur; Brian Carter; Robert N Hoover; Stephen J Chanock; Sharon A Savage Journal: JAMA Oncol Date: 2020-05-01 Impact factor: 31.777
Authors: Mark Robson; Seock-Ah Im; Elżbieta Senkus; Binghe Xu; Susan M Domchek; Norikazu Masuda; Suzette Delaloge; Wei Li; Nadine Tung; Anne Armstrong; Wenting Wu; Carsten Goessl; Sarah Runswick; Pierfranco Conte Journal: N Engl J Med Date: 2017-06-04 Impact factor: 91.245
Authors: Marilyn M Li; Elizabeth Chao; Edward D Esplin; David T Miller; Katherine L Nathanson; Sharon E Plon; Maren T Scheuner; Douglas R Stewart Journal: Genet Med Date: 2020-04-23 Impact factor: 8.822
Authors: Shazia S Mahamdallie; Sandra Hanks; Kristen L Karlin; Anna Zachariou; Elizabeth R Perdeaux; Elise Ruark; Chad A Shaw; Alexander Renwick; Emma Ramsay; Shawn Yost; Anna Elliott; Jillian Birch; Michael Capra; Juliet Gray; Juliet Hale; Judith Kingston; Gill Levitt; Thomas McLean; Eamonn Sheridan; Anthony Renwick; Sheila Seal; Charles Stiller; Neil Sebire; Thomas F Westbrook; Nazneen Rahman Journal: Nat Genet Date: 2015-11-09 Impact factor: 38.330